{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurotransmitter+Agents&page=2",
    "query": {
      "condition": "Neurotransmitter Agents",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurotransmitter+Agents&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:16:36.603Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04032301",
      "title": "Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Post-Traumatic Stress Disorders",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 67,
      "start_date": "2019-09-30",
      "completion_date": "2024-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032301"
    },
    {
      "nct_id": "NCT01366196",
      "title": "Pregabalin for the Treatment of Pain After Posterior Spinal Fusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lumbar Spinal Fusions"
      ],
      "interventions": [
        {
          "name": "Pregabalin 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2008-10",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366196"
    },
    {
      "nct_id": "NCT07122193",
      "title": "A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromuscular Agents",
        "Peripheral Nervous System Agents",
        "Physiological Effects of Drugs",
        "Acetylcholine Release Inhibitors",
        "Membrane Transport Modulators",
        "Molecular Mechanisms of Pharmacological Action",
        "Cholinergic Agents",
        "Neurotransmitter Agents",
        "incobotulinumtoxinA",
        "Botulinum Toxins, Type A"
      ],
      "interventions": [
        {
          "name": "NT 201",
          "type": "DRUG"
        },
        {
          "name": "NT 201 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz North America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-08-27",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 27,
      "location_summary": "Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07122193"
    },
    {
      "nct_id": "NCT05321602",
      "title": "Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders",
        "Mood Disorders",
        "Schizophrenia Spectrum and Other Psychotic Disorders",
        "Mental Disorders",
        "Antipsychotic Agents",
        "Tranquilizing Agents",
        "Central Nervous System Depression",
        "Physiological Effects of Drugs",
        "Psychotropic Drugs",
        "Neurotransmitter Agents",
        "Molecular Mechanisms of Pharmacological Action"
      ],
      "interventions": [
        {
          "name": "LY03010 156 mg treatment group, deltoid",
          "type": "DRUG"
        },
        {
          "name": "LY03010 156 mg treatment group, gluteal",
          "type": "DRUG"
        },
        {
          "name": "LY03010 351 mg treatment group, deltoid",
          "type": "DRUG"
        },
        {
          "name": "LY03010 351 mg treatment group, gluteal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 89,
      "start_date": "2021-09-08",
      "completion_date": "2022-10-23",
      "has_results": false,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05321602"
    },
    {
      "nct_id": "NCT02045264",
      "title": "Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "Icatibant (30 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-02-21",
      "completion_date": "2014-02-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045264"
    },
    {
      "nct_id": "NCT05615948",
      "title": "Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Treatment Resistant Depression",
        "Major Depressive Disorder",
        "Analgesia",
        "Ketamine",
        "Peripheral Nervous System Agents",
        "Central Nervous System Depressants",
        "Neurotransmitter Agents",
        "Anti-Inflammatory Agents",
        "Physiological Effects of Drugs",
        "Sensory System Agents",
        "Analgesics, Non-Narcotic",
        "Anti-Inflammatory Agents, Non-Steroidal",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "VTS-K",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theresa Jacob, PhD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 15,
      "start_date": "2022-12-06",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05615948"
    },
    {
      "nct_id": "NCT03610282",
      "title": "EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anesthesia"
      ],
      "interventions": [
        {
          "name": "IV Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Propofol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-11",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2020-02-21",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03610282"
    },
    {
      "nct_id": "NCT01953432",
      "title": "Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Doxazosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 43,
      "start_date": "2014-04-01",
      "completion_date": "2017-10-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01953432"
    },
    {
      "nct_id": "NCT03250117",
      "title": "Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Ropinirole oral product",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole Implant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Titan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-10-10",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03250117"
    },
    {
      "nct_id": "NCT02227368",
      "title": "Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Artery Disease (PAD)"
      ],
      "interventions": [
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        },
        {
          "name": "Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "50 Years to 130 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-10-20",
      "completion_date": "2016-05-23",
      "has_results": true,
      "last_update_posted_date": "2017-07-19",
      "last_synced_at": "2026-06-11T04:16:36.603Z",
      "location_count": 10,
      "location_summary": "Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227368"
    }
  ]
}